Merck (MRK) Amortizatization of Intangibles (2020 - 2026)
Merck (MRK) posted quarterly Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% year-over-year from $597.0 million in Q1 2025, and down 4.32% quarter-over-quarter from $973.0 million in Q4 2025.
Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Merck (MRK) has reported Amortizatization of Intangibles for 7 consecutive years, with $931.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 55.95% year-over-year to $931.0 million; the TTM figure through Mar 2026 stood at $3.1 billion (up 24.18% YoY), while the FY2025 annual figure was $2.8 billion, up 16.62% from the prior year.
- Amortizatization of Intangibles slipped to $931.0 million in Q1 2026 per MRK's latest filing, from $973.0 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $973.0 million in Q4 2025 and bottomed at $460.0 million in Q3 2022.
- Historically, Amortizatization of Intangibles has averaged $602.8 million across 5 years, with a median of $597.0 million in 2025.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles declined 22.32% — and 2026, when it soared 55.95%.
- Merck's Amortizatization of Intangibles stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then surged by 46.1% to $675.0 million in 2024, then soared by 44.15% to $973.0 million in 2025, then slipped by 4.32% to $931.0 million in 2026.
- Business Quant data shows MRK's Amortizatization of Intangibles at $931.0 million in Q1 2026, $973.0 million in Q4 2025, and $623.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 600.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 984.00 Mn |
| Jun 30, 2026 | 984.00 Mn |
| Mar 31, 2026 | 931.00 Mn |
| Mar 31, 2026 | 931.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Mar 31, 2024 | 473.00 Mn |